Close Menu
    Trending
    • IGEL Reaches Unicorn Status with Strategic Investment from Vitruvian Partners to Accelerate Growth of its Endpoint Security and Cyber Resilience Endpoint Platform for Enterprise
    • Booking Holdings Unveils Booking Partner Division to Accelerate B2B Travel Innovation
    • Ebola adds 60 cases in a day as Congo deaths hit 5,568
    • Dubai Airports expects over 70 million guests in 2026
    • Rand slips toward R17 as inflation and weak growth cloud outlook
    • Sinopec Co-Hosts Final of Youth Cultural Ambassador Competition in Algiers
    • Sokin expands in the UAE with DFSA license, local AED payment rails and accounts
    • Tencent Cloud Powers HooLive to Deliver Enhanced Digital Entertainment Experiences in Saudi Arabia
    • Home
    • Contact Us
    Irani TimesIrani Times
    Wednesday, November 18
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Irani TimesIrani Times
    Home » CanariaBio Announces Enrollment Completion of Phase 2 Study of Oregovomab in Combination With Niraparib in the Treatment of Recurrent Ovarian Cancer
    ACCESS Newswire

    CanariaBio Announces Enrollment Completion of Phase 2 Study of Oregovomab in Combination With Niraparib in the Treatment of Recurrent Ovarian Cancer

    August 8, 2023
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    SEOUL, SOUTH KOREA / ACCESSWIRE / August 8, 2023 / CanariaBio, a KOSDAQ-listed and a leading late-stage biotechnology company, announces the successful enrollment completion of a Phase 2 study of Oregovomab in combination with niraparib, GSK’s poly (ADP-ribose) polymerase (PARP) inhibitor, for treatment of patients with platinum-sensitive recurrent ovarian cancer.

    CanariaBio Inc., Tuesday, August 8, 2023, Press release picture

    This trial, known as FLORA-4 (NCT05335993), is being conducted by CanariaBio, with GSK providing clinical trial supply of niraparib. The study will assess the immunological and clinical activity, early humoral response, and disease control rate of concomitant Oregovomab and daily oral niraparib. This will be a preliminary investigation of the interaction of indirect immunization with Oregovomab and concomitant niraparib therapy and the immune modulatory effects associated with PARP inhibition. The key aim of the study is to explore whether a non-chemotherapy combination of Oregovomab and niraparib would potentially extend the platinum-free interval, which is known to have a favorable impact on subsequent treatment with platinum-based combination chemotherapy.

    Ovarian cancer is known for its high recurrence rate. In this difficult landscape, Oregovomab has the potential of emerging as a promising immunotherapeutic agent. Through rigorous Phase II clinical trials, Oregovomab has not only demonstrated its safety profile but also showcased remarkable results by extending PFS by approximately 30 months when combined with chemotherapy, compared to conventional chemotherapy alone.

    About Oregovomab

    Oregovomab is a murine monoclonal antibody against CA 125, a biomarker commonly found in ovarian cancer. Indirect immunization with Oregovomab interacts with immune-modulating properties of infused paclitaxel and carboplatin, resulting in synergistic clinical benefits as observed in a Phase II trial. In a randomized Phase II clinical trial of 97 patients, treatment with Oregovomab in combination with chemotherapy had demonstrated a highly statistically significant and clinically meaningful outcome for both progression-free and overall survival compared to standard-of-care chemotherapy (carboplatin and paclitaxel). The risk of progression and of death was reduced by more than 50% when compared to control arm, and safety data showed that Oregovomab did not add incremental toxicity to the chemotherapy regimen. Clinical and translational results were published in Gynecology Oncology (2020) 156:523-529 and Cancer Immunology and Immunotherapy (2020) 69: 383-397, respectively.

    About ZEJULA (niraparib)

    Niraparib is an oral, once-daily poly (ADP-ribose) polymerase inhibitor approved by FDA and EMA for the use in ovarian cancer, marketed as ZEJULA by GSK. Niraparib is currently being evaluated in multiple pivotal trials. GSK is building a robust clinical development programme by assessing activity across multiple tumour types and evaluating several potential combinations of niraparib with other therapeutics. For questions or more information on niraparib, please visit www.gsk.com.

    About CanariaBio Inc.

    CanariaBio Inc. is a Korean biopharmaceutical company focused on the development and commercialization of immunotherapies for cancer. CanariaBio’s technology platform includes a portfolio of tumor antigen-specific monoclonal immunoglobulins targeting CA-125, MUC1, PSA and Her2/neu. The company is exploring the therapeutic potential of these antibodies as indirect immunizers in combination with other immune-modulating drugs or drug combinations to address unmet medical needs in oncology.

    Forward-Looking Statements

    This press release includes forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. These statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. The information in this release is provided only as of the date of this release and the company undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.

    Contact Information

    Jacquelyn Choi
    PR Manager
    ipr@canariabio.com

    Related Files

    CanariaBio Announces Enrollment Completion News_08.08.23.docx

    SOURCE: CanariaBio Inc.

    .

    Related Posts

    Chevron Signs 3-Year Agreement with UptimeAI, Scaling Expertise to Enhance Asset Reliability and Operational Efficiency

    November 17, 2026

    Pitches and Keynote Speakers Are Confirmed for Blue Magic Netherlands on November 17

    November 4, 2026

    Chervon Names Jody Grimsley Senior National Account Manager

    November 2, 2026

    GA-ASI and Saab Perform Advanced AEW Flight Testing on Uncrewed MQ-9B

    October 28, 2026

    Chervon Names Parker Wesley Clary Director of Field Sales – Southern Division

    October 26, 2026

    Study Finds Lower Rates of Overweight Among Vegan-Fed Cats

    October 23, 2026
    Latest News

    Ebola adds 60 cases in a day as Congo deaths hit 5,568

    November 18, 2026

    Dubai Airports expects over 70 million guests in 2026

    November 18, 2026

    Rand slips toward R17 as inflation and weak growth cloud outlook

    November 18, 2026

    Over 9 million visitors lift Tunisia tourism income 3.4%

    November 17, 2026
    © 2026 Irani Times | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.